Hypera Pays $825m For Takeda LatAm Portfolio

Post-Shire Divestments Reach $7.4bn

Major new portfolio divestment, along with Deerfield site sale, form part of ongoing effort to pay down Shire-related debt and focus on novel drugs.

BrazilMap_1200x675
New Takeda Divestments Include Products In Brazil, LatAm • Source: Shutterstock

Separately, the Japanese firm has also sold its former US headquarters in Deerfield, IL for $115m to Ireland-based Horizon Therapeutics PLC.

The $825m deal with Hypera comprises what the Japanese firm considers to be non-core over-the-counter and prescription pharmaceutical products in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.